New cocktail of four drugs takes on tough pancreatic cancer
NCT ID NCT05669482
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 33 times
Summary
This early-phase trial is testing a combination of four drugs—two standard chemotherapy drugs plus two newer targeted agents—in 40 people with metastatic pancreatic cancer that hasn't been treated before. The goal is to find a safe dose and see if the combination can shrink tumors. It's a small, early study, so results will guide future research rather than offer a new treatment right away.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREAS CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Fred Hutchinson Cancer Center
Seattle, Washington, 98109, United States
-
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health
New York, New York, 10016, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
New York Presbyterian/Weill-Cornell Medical Center
New York, New York, 10021, United States
-
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California, 94158, United States
-
University of Chicago
Chicago, Illinois, 60637, United States
-
University of Michigan Cancer Center
Ann Arbor, Michigan, 48109, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
University of Utah Huntsman Cancer Institute
Salt Lake City, Utah, 84112, United States
-
Virginia Mason Medical Center
Seattle, Washington, 98101, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
avutometinib and defactinib combined with gemcitabine and nab-paclitaxel
What this could lead to
If it works, this could point toward a new treatment option for people with advanced pancreatic cancer that hasn't been treated yet.
What could go wrong
This is an early-phase trial with only 40 people, so it's too soon to know if the combination is truly effective or safe. Side effects from the drugs could be serious.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.